SYDNEY, June 27, 2026, 07:02 AEST
- Cochlear finished the session Friday at A$118.03, rising 1.27% for the day. Shares are still off 0.1% compared to last Friday. Investing
- Average volume over five sessions hit about 661,000 shares, which is 2.5 times its typical 12-month daily average. Investing
- S&P/ASX 200 ended the week down 0.7% at 8,764.20. Investing
- Cochlear has a market cap of A$7.72 billion, or roughly 25 times the midpoint of the company’s reduced FY26 profit guidance. Intelligent Investor
Cochlear Limited ASX:COH finished the ASX week nearly flat, but the numbers tell a choppier story. Shares slipped 0.1% over the week to A$118.03, barely changed from last Friday’s close at A$118.14. The stock dropped 4.38% on Monday and rebounded 4.5% by Friday’s finish. Investing
The S&P/ASX 200 (INDEXASX:XJO) dropped 0.7% from last Friday to this Friday, moving from 8,828.70 to 8,764.20. Cochlear managed to do a little better than the index this week, but it wasn’t by much. The stock is still working its way back after the profit warning in April. Investing
Cochlear’s trading volume jumped. About 3.30 million shares changed hands in five sessions, or an average of 661,000 a day. That’s around 2.5 times the 12-month daily average of 268,319 shares, according to Intelligent Investor. Investing
Cochlear had a market cap of A$7.72 billion at Friday’s close. The shares trade at around 25 times the midpoint of Cochlear’s cut FY26 underlying net profit forecast, or A$310 million. That’s still a premium multiple for a medical device company, even though the share price has dropped sharply. The market continues to factor in a rebound rather than slow growth. Intelligent Investor
The numbers are stark. Intelligent Investor lists a 52-week high of A$319.42 and a low of A$90.00. The stock finished Friday 63.05% under the high and 31.14% up from the low. Intelligent Investor
Cochlear dropped its FY26 underlying net profit target in April to A$290 million to A$330 million, down from its previous range of A$435 million to A$460 million. The company blamed lower sales, weaker gross margin, a stronger Australian dollar, and possible Middle East receivables provisions for the cut. ASX Announcements
April’s update wasn’t all negative. Services revenue climbed 13% in the third quarter on a constant currency basis. Acoustics revenue gained 11%. Cochlear implant revenue in developed markets held steady, flat in constant currency, as the company pointed to surgery capacity and fewer hearing-aid referrals. ASX Announcements
CEO and President Dig Howitt said “the clinical need for cochlear implants continues to grow” in the update. He added “market share has been improving” since the Nucleus Nexa System launch, after an earlier contraction across developed markets. ASX Announcements
Cochlear’s analyst range still looks broad, but the average upside is not big. Investing.com shows 16 analyst targets for the stock, starting at A$95 and running to A$170. The average target of A$127.18 is about 7.75% above Friday’s close. Investing
No big reports this week to shift forecasts. Cochlear is set to give its 2026 full-year results on Aug. 18, and the annual meeting is Oct. 26. Cochlear
Next up for ASX is how the stock trades on price and turnover. Staying above A$115 keeps it in Friday’s range. A move above A$118.76 takes it past Friday’s intraday high. Investing
